Jakarta – Hospitalization costs for a single COVID-19 client requiring long-term treatment might swell to Rp446 million, an academic from the University of Indonesia (UI) has actually declared.
” My study in nine provinces has exposed that the greatest health care expense borne by a COVID-19 patient was recorded at Rp446 million,” Prof. Dr. Hasbullah Thabrany, MPH, from UI’s Professors of Public Health told a webinar arranged on the theme of “computing healthcare costs” here on Monday.
The typical health care expenses for a COVID-19 patient hospitalized for 16 days were taped at Rp184 million, Thabrany said, including that the study covered several thousand patients diagnosed with COVID-19
Typically, COVID-19 clients were hospitalized for 15.4 days, but some wound up investing as much as 194 days in the health center, he notified. The hospitalization costs for clients might vary from Rp2.4 million to Rp446 million, he added.
The cost of hospitalization a COVID-19 patient has to bear would depend on the state of his or her health at the time of contracting the infection, he noted adding, the existence of comorbidities might contribute to health care expenses.
In view of the high health care expenses borne by the patients, Thabrany advised neighborhood members to remain conscious of the importance of preventive procedures and consistently execute the mandated health procedures to break the chain of COVID-19 spread.
The novel coronavirus disease at first struck the Chinese city of Wuhan at the end of 2019 and thereafter spread throughout the world, including to nations in the Asia-Pacific area.
The Indonesian federal government made a main statement on the country’s first confirmed cases on March 2 this year.
The Indonesian government has regularly revealed confidence in the potential of COVID-19 vaccines for helping it win the fight versus the COVID-19 pandemic, which has presented a severe danger to public health and the economy.
Over the previous few months, the federal government has made full-blown efforts to secure possible COVID-19 vaccines for Indonesians through bilateral and multilateral cooperation.
The federal government is also supporting research efforts towards developing the nation’s own COVID-19 vaccine, Merah Putih (Red and White), named after the colors of the national flag.
Indonesia is cooperating with China and the United Kingdom for the procurement and supply of COVID-19 vaccine candidates.
An Indonesian delegation protected access to COVID-19 vaccines from China throughout a conference with representatives from Cansino, G42, Sinopharm, and Sinovac in China on October 10 this year.
As divulged by Coordinating Minister for Maritime Affairs and Investment, Luhut Binsar Pandjaitan, the federal government would likely commence the very first stage of COVID-19 immunization in the third week of December,2020 (INE)
Associated news: 4,233 hotel rooms prepared for COVID-19 clients, healthcare employees
Related news: Pharmacist Association points to 800 pharmacists exposed to COVID-19
EDITED BY INE
